MedPath

Test to Treat TB: Impact of sputum sequencing-guided individualised therapy on outcomes in drug-resistant tuberculosis (TB): a proof of concept randomised controlled trial

Phase 2
Not yet recruiting
Conditions
Tuberculosis
Registration Number
PACTR201811667026997
Lead Sponsor
CT Lung Institute
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
280
Inclusion Criteria

•Newly diagnosed culture and/or Xpert/MTB Ultra positive pulmonary TB
•Rifampicin mono-resistance detected using the results from two susceptibility-testing assays (GeneXpert, HainMTBDRplus or phenotypic DST). This will be done on a sputum sample during screening, or with pre-existing results available from the local health care service.
•Provide written informed consent prior to all trial-related procedures
•Male or female aged 18 years and older.
•Patients on TB treatment for less then 8 days.

Exclusion Criteria

•A subject who in the opinion of the investigator is unlikely to cope with regular visits to the trial site either because of travel constraints, or drug or alcohol abuse, or other reason.
•Currently on MDR-TB treatment for more than 2 weeks.
•Any participant with a clinically significant medical condition that, in the opinion of the investigator, may be negatively affected by the patient’s participation in the study.
•Any subject with a Karnofsky score < 50.
•Having participated in other clinical studies within 8 weeks prior to trial start where investigational agents were used that may potentially impact current trial outcome.
•Participant who is pregnant, breast-feeding (and not willing to stop), or planning to conceive a child within 6 months of cessation of treatment.
•Any pre-existing laboratory abnormality, which in the opinion of the investigator will place the participant at risk (see detailed protocol for grade of abnormality).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.